Ryan Cross

about the author

Senior Science Correspondent

rcross@endpointsnews.com

Ryan Cross is the Senior Science Correspondent at Endpoints News. He joined the newsroom in 2023 after covering biotech for The Boston Globe. Before that he was at Chemical & Engineering News where he led coverage of COVID vaccines, gene editing, and all things RNA. His work has also appeared in MIT Technology Review, Science, STAT, and more. Ryan is a graduate of Boston University's master's program in science journalism, and he studied genetics, neuroscience, and medicinal chemistry at Purdue University. He is from Indiana and currently lives in Cambridge, Massachusetts.

author articles

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

18 hours ago

R&D

Cell/Gene Tx

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Yesterday

Deals

R&D

In Focus

First-of-its-kind gene therapy approved for healing wounds in “butterfly children”

3 weeks ago

R&D

Cell/Gene Tx

After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline

3 weeks ago

R&D

Cell/Gene Tx

Patient who received custom gene therapy likely died from immune reaction, not CRISPR, paper says

3 weeks ago

R&D

Cell/Gene Tx

Startups

about the author

Ryan Cross

Senior Science Correspondent

author articles

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23

J&J’s bladder cancer drug Balversa cuts the risk of death in follow-up trial: #ASCO23

Servier’s vorasidenib stalls progression of brain cancer by 61% in pivotal PhIII INDIGO study: #ASCO23

Keytruda before and after lung cancer surgery cuts relapse risk by 42%, but doesn’t improve survival: #ASCO23

Grail’s blood test charts path for diagnosing patients suspected of having cancer in large study: #ASCO23

Bristol Myers details PhIII win in first-line test of Reblozyl for reducing transfusions in early blood cancer ...

Rich Horgan spearheaded a gene therapy for his brother. The trial ended in tragedy, but the work continues for more ...

First-of-its-kind gene therapy approved for healing wounds in “butterfly children”

After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline

Patient who received custom gene therapy likely died from immune reaction, not CRISPR, paper says

Colombian man's genetics should have doomed him to Alzheimer's. Instead, a rare mutation offers clue to protection

Enanta is looking for a partner on its Covid pill after a PhII study disappoints

“The grim veil has been lifted.” Excitement, and questions, mount over Lilly’s positive Alzheimer’s drug data

Lilly’s Alzheimer’s drug donanemab slows cognitive decline by 35% in PhIII, setting up showdown with Eisai’s ...

Durham startup raises Series A to tackle undruggable proteins, including cancer baddie Myc, with generative AI

MD Anderson, Flagship startup partner to design and test cancer drugs made with generative AI

In victory for microbiome company, FDA approves pills purified from poop

Early results from Alzheimer’s study set stage for Alnylam’s expansion into brain diseases